TWI831780B - 嘧啶衍生物之醫藥鹽及治療病症之方法 - Google Patents

嘧啶衍生物之醫藥鹽及治療病症之方法 Download PDF

Info

Publication number
TWI831780B
TWI831780B TW108116512A TW108116512A TWI831780B TW I831780 B TWI831780 B TW I831780B TW 108116512 A TW108116512 A TW 108116512A TW 108116512 A TW108116512 A TW 108116512A TW I831780 B TWI831780 B TW I831780B
Authority
TW
Taiwan
Prior art keywords
compound
salt
succinate
crystalline form
pharmaceutically acceptable
Prior art date
Application number
TW108116512A
Other languages
English (en)
Chinese (zh)
Other versions
TW202015687A (zh
Inventor
蘭登 Ｊ 杜拉
瑪莉恩 蘭斯登
普來廸 庫瑪 雪爾瑪
太義 阮
雙蓮 李
曉功 張
Original Assignee
日商武田藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商武田藥品工業股份有限公司 filed Critical 日商武田藥品工業股份有限公司
Publication of TW202015687A publication Critical patent/TW202015687A/zh
Application granted granted Critical
Publication of TWI831780B publication Critical patent/TWI831780B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW108116512A 2018-05-14 2019-05-14 嘧啶衍生物之醫藥鹽及治療病症之方法 TWI831780B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
US62/671,182 2018-05-14
US62/671,166 2018-05-14

Publications (2)

Publication Number Publication Date
TW202015687A TW202015687A (zh) 2020-05-01
TWI831780B true TWI831780B (zh) 2024-02-11

Family

ID=68540756

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108116512A TWI831780B (zh) 2018-05-14 2019-05-14 嘧啶衍生物之醫藥鹽及治療病症之方法

Country Status (11)

Country Link
US (1) US12084431B2 (enExample)
EP (2) EP4234547A3 (enExample)
JP (2) JP2021523208A (enExample)
KR (1) KR20200144579A (enExample)
CN (1) CN112313223A (enExample)
AU (1) AU2019269372A1 (enExample)
BR (1) BR112020023107A2 (enExample)
CA (1) CA3099737A1 (enExample)
MX (1) MX2020012063A (enExample)
TW (1) TWI831780B (enExample)
WO (1) WO2019222093A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR20220011663A (ko) * 2019-05-22 2022-01-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 인돌 유도체-함유 억제제, 이의 제조 방법 또는 이의 적용
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A4 (en) * 2021-07-07 2025-04-30 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor
MX2024000261A (es) * 2021-08-06 2024-03-14 Abbisko Therapeutics Co Ltd Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195228A1 (en) * 2014-06-19 2015-12-23 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788629T2 (de) 1986-03-31 1994-04-28 Rhone Poulenc Bv Neue malonsäurederivate und zusammensetzungen, die sie enthalten, zur verzögerung des pflanzenwachstums.
JP2749578B2 (ja) 1986-03-31 1998-05-13 ローヌープーラン・ネーデルランド・ベー・ベー 相乗的植物成長調節剤組成物
JPS63503070A (ja) 1986-03-31 1988-11-10 ローヌープーラン・ネーデルランド・ベー・ベー マロン酸誘導体化合物の作物収穫量を増大させるための使用
WO2000006555A1 (en) 1998-07-30 2000-02-10 American Home Products Corporation Substituted quinazoline derivatives
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
WO2003097855A2 (en) 2002-05-14 2003-11-27 Baylor College Of Medicine Small molecule inhibitors of her2 expression
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP2008510719A (ja) 2004-08-19 2008-04-10 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
EP1951672B1 (en) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Potassium channel inhibitors
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
JP2012517448A (ja) 2009-02-11 2012-08-02 リアクション バイオロジー コープ． 選択的キナーゼ阻害剤
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
EP2430013B1 (en) 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
US9840517B2 (en) 2013-09-18 2017-12-12 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of BTK and/or JAK3 kinases
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
JP2017507983A (ja) 2014-03-18 2017-03-23 アイティーオス セラペウティクス 新規な３−インドール置換誘導体、医薬組成物、および使用方法
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
PL3205650T3 (pl) 2014-10-11 2021-12-06 Shanghai Hansoh Biomedical Co., Ltd. Inhibitor EGFR i jego otrzymywanie i zastosowanie
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑
CN106995437A (zh) 2016-01-22 2017-08-01 齐鲁制药有限公司 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
CN110248934B (zh) * 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195228A1 (en) * 2014-06-19 2015-12-23 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition

Also Published As

Publication number Publication date
WO2019222093A1 (en) 2019-11-21
CN112313223A (zh) 2021-02-02
EP3793993A4 (en) 2022-01-05
AU2019269372A1 (en) 2020-11-26
US20210309640A1 (en) 2021-10-07
TW202015687A (zh) 2020-05-01
KR20200144579A (ko) 2020-12-29
EP4234547A2 (en) 2023-08-30
JP2024051160A (ja) 2024-04-10
MX2020012063A (es) 2021-04-13
EP3793993A1 (en) 2021-03-24
BR112020023107A2 (pt) 2021-02-02
US12084431B2 (en) 2024-09-10
JP2021523208A (ja) 2021-09-02
EP4234547A3 (en) 2023-11-01
CA3099737A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
US12084431B2 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP2022106967A (ja) 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
KR102090453B1 (ko) 상피 성장 인자 수용체 키나제 억제제의 염
TW202110836A (zh) 固態形式
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
TW201700492A (zh) 用於治療癌症之核苷酸
TWI503121B (zh) 用以治療癌症之組成物及方法
AU2012228439B9 (en) Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (SYK)
WO2012123311A1 (en) Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
TWI888447B (zh) 金屬鹽及其用途
WO2019196619A1 (zh) 喹唑啉衍生物盐型晶型及制备方法和应用
JP2022548689A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
HK40046158A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
HK40096550A (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
WO2020216669A1 (de) Phenylsubstituierte imidazopyridinamide und ihre verwendung
JP2025526688A (ja) 疾患を治療するためのモノカルボン酸トランスポータ４の複素環式阻害剤の塩
CN120623146A (zh) 一种氘代酰胺类化合物及其制备方法和应用
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
HK1254731B (zh) 用於医学应用的一种1，2，4-三唑并[4，3-a]吡啶的衍生物的新型结晶盐形式

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees